Chardan Capital Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $6

Futu NewsNov 19 16:36 · Ratings

Gain Therapeutics Advances Parkinson's Therapy Development

TipRanksNov 19 11:57

Gain Therapeutics Receives Buy Rating as GT-02287 Shows Promise for GBA1 Parkinson's Disease

TipRanksNov 19 09:05 · Ratings

Gain Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results.

BenzingaNov 15 21:23

Gain Therapeutics Q3 2024 GAAP EPS $(0.17) Beats $(0.21) Estimate

BenzingaNov 15 05:17

Gain Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 15 05:11 · Announcements